RenovoRx, Inc. (NASDAQ:RNXT – Get Free Report) shot up 5.1% on Monday . The company traded as high as $1.28 and last traded at $1.23. 4,335 shares changed hands during mid-day trading, a decline of 93% from the average session volume of 60,210 shares. The stock had previously closed at $1.17.
Analyst Ratings Changes
Separately, Alliance Global Partners initiated coverage on shares of RenovoRx in a research report on Friday, February 2nd. They set a “buy” rating and a $4.00 target price on the stock.
Check Out Our Latest Research Report on RNXT
RenovoRx Stock Performance
Hedge Funds Weigh In On RenovoRx
A hedge fund recently bought a new stake in RenovoRx stock. Nixon Peabody Trust Co. purchased a new position in shares of RenovoRx, Inc. (NASDAQ:RNXT – Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 97,165 shares of the company’s stock, valued at approximately $223,000. Nixon Peabody Trust Co. owned 0.91% of RenovoRx as of its most recent SEC filing. 3.10% of the stock is owned by hedge funds and other institutional investors.
About RenovoRx
RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
Further Reading
- Five stocks we like better than RenovoRx
- Best Stocks Under $10.00
- High-Yield Texas Instruments Could Hit New Highs Soon
- Overbought Stocks Explained: Should You Trade Them?
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- 3 Fintech Stocks With Good 2021 Prospects
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for RenovoRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RenovoRx and related companies with MarketBeat.com's FREE daily email newsletter.